Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial – Bristol-Myers Squibb July 11, 2023
ASCO: Seagen’s top-selling drug under threat as Bristol Myers’ Opdivo beats Adcetris in lymphoma – FiercePharma June 4, 2023